May 27, 2022 – In January 2021, the Department of Health and Human Services (HHS) published a strategic plan to eliminate viral hepatitis by 2030. Hospitals participating in the 340B drug pricing program are a key element of that ambitious goal. They are using their 340B savings to achieve measurable improvements in health outcomes for patients with hepatitis C. National … [Read more...]
Research Demonstrates 340B Hospitals’ Work to Serve the Underserved
June 25, 2021– Tens of millions of people in the U.S. who are living with chronic diseases require access to regular care and support to help them manage their conditions and live their best possible lives. For too many patients of color, those living with disabilities, and those who have low incomes, the broader health care system often falls short in providing them the care … [Read more...]
Faces of 340B: Coming Full Circle
July 28, 2020 – The opioid epidemic over the last decade has resulted in a spike in hepatitis C infections, which the Centers for Disease Control and Prevention reports have more than tripled since 2010. Public health and infectious disease experts believe that the common practice of sharing needles among people using opioids is a significant contributing factor to the rise in … [Read more...]
340B May Curb High Drug Prices, New JAMA Study Finds
July 9, 2019– The 340B drug pricing program may discourage drug manufacturers from raising prices and instead may have the effect of reducing list prices for certain drugs. That’s according to a new study published in the Journal of the American Medical Association (JAMA). Study authors Sean Dickson of West Health and Ian Reynolds of the Pew Charitable Trusts evaluated the … [Read more...]
Faces of 340B: Going Above and Beyond
May 24, 2019— The mission of Catholic Health System based in Buffalo, N.Y., is to treat all patients with respect and dignity regardless of what brings them through the doors. That’s why the Mount St. Mary’s Neighborhood Health Center in Niagara Falls, at one of the system’s five hospitals, goes “above and beyond” to help patients living with drug and alcohol use disorders, … [Read more...]
340B Helps Achieve Hepatitis C “Gold Standard” At Boston Medical Center
May 17, 2019– A recent study highlights how the 340B drug pricing program helps a safety-net hospital provide critical treatment to patients with Hepatitis C (HCV) and improve health outcomes. Published in the journal PLOS ONE, researchers at Boston Medical Center (BMC) found that the hospital’s 340B savings enabled them to operate a primary-care based multidisciplinary HCV … [Read more...]